Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
The DOI matches its Crossref record.
Abstract
PURPOSE: We studied the prognostic significance of bcl2 and p53 protein expression in relation to clinical and pathologic characteristics in patients with diffuse large B-cell lymphoma (LCL). PATIENTS AND METHODS: Three hundred seventy-two patients with LCL were retrieved from a population-based registry for non-Hodgkin's lymphoma (NHL). bcl2 and p53 protein expression was studied on paraffin-embedded tumor tissue by immunohistochemistry in relation to clinical factors. Response to therapy and survival were analyzed in 165 patients who were uniformly staged and treated and for whom all prognostic data were available according to the International Prognostic Index (IPI). RESULTS: Forty-five percent of tumors showed strong expression of the bcl2 protein (bcl2++), with a higher frequency in patients with primary nodal involvement. Disease-free survival (DFS) was significantly better in bcl2-negative/intermediate (bcl2-/+) cases as compared with bcl2++ cases (P = .0011). At 5 years, bcl2-/+ patients showed a DFS rate of 74%, in contrast to bcl2++ patients with a DFS rate of 41% (P = .002). Bcl2 was the strongest independent prognostic value in a multivariate analysis, with a relative risk (RR) of 3.0 in comparison to p53 expression and the clinical factors of the IPI. Overall survival (OS) was not significantly influenced by bcl2 protein expression. p53 protein expression was found in 13% of cases, with a higher frequency in patients with extensive disease. p53 expression did not influence the chance to achieve complete remission (CR) and survival. CONCLUSION: bcl2 protein is frequently expressed in LCL and is a strong independent prognostic factor for DFS. p53 expression is related with high tumor burden, but is not an independent risk factor for CR and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Hans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., & Levy, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032520 · Cited by 911
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M., & Letai, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 513
Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E., Tolcher, A. W., O'Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J. C., et al. (1997) · Blood · doi:10.1182/blood.v90.1.244 · Cited by 509
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
Kramer, M. H. H., Hermans, J., Wijburg, E., Philippo, K., Geelen, E., van Krieken, J. H. J. M., de Jong, D., Maartense, E., Schuuring, E., & Kluin, P. M. (1998) · Blood · doi:10.1182/blood.v92.9.3152 · Cited by 499
Self-citationColomo, L., López-Guillermo, A., Perales, M., Rives, S., Martı́nez, A., Bosch, F., Colomer, D., Falini, B., Montserrat, E., & Campo, E. (2003) · Blood · doi:10.1182/blood-2002-04-1286 · Cited by 391
Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Adida, C., Haïoun, C., Gaulard, P., Lepage, É., Morel, P., Brière, J., Dombret, H., Reyes, F., Diebold, J., Gisselbrecht, C., et al. (2000) · PubMed · doi:10.1182/blood.v96.5.1921 · Cited by 359
de Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., Sander, B., Thorns, C., Campo, E., Molina, T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4490 · Cited by 301
Self-citationLossos, I. S., Jones, C. D., Warnke, R., Natkunam, Y., Kaizer, H., Zehnder, J. L., Tibshirani, R., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.4.945 · Cited by 288
Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A. P., Morgan, G. J., & Jack, A. S. (2002) · Blood · doi:10.1182/blood.v99.4.1136 · Cited by 276
Muris, J., Meijer, C., Vos, W., van Krieken, J., Jiwa, N., Ossenkoppele, G., & Oudejans, J. (2006) · The Journal of Pathology · doi:10.1002/path.1924 · Cited by 233
Self-citationNegative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221
“Low grade lymphomas also express mutated p53, although the number ranges from 3 ± 33% in di erent studies (Ilyas et al., 1996; Kramer et al., 1996; Nguyen et al., 1996; Said et al., 1992; Soini et al., 1992; Takano et al., 1997; Villeundas et al., 1992) and there is heterogeneity of expression…”
BackgroundFalini, B., & Mason, D. Y. (2002) · Blood · doi:10.1182/blood.v99.2.409 · Cited by 195
Metadata
- Authors
- Kramer, M. H., Hermans, J., Parker, J., Krol, A. D., Kluin-Nelemans, J. C., Haak, H. L., van Groningen, K., van Krieken, J. H., de Jong, D., & Kluin, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-07
- Volume
- 14
- Issue
- 7
- Pages
- 2131-2138
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1892527323
- Cited by
- 201
- References
- 0
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.